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Abstract
Inclusions in the brain containing a-synuclein are the pathological hallmark of Parkinson’s disease, but how these inclusions
are formed and how this links to disease is poorly understood. We have developed a C. elegans model that makes it possible
to monitor, in living animals, the formation of a-synuclein inclusions. In worms of old age, inclusions contain aggregated a-
synuclein, resembling a critical pathological feature. We used genome-wide RNA interference to identify processes involved
in inclusion formation, and identified 80 genes that, when knocked down, resulted in a premature increase in the number of
inclusions. Quality control and vesicle-trafficking genes expressed in the ER/Golgi complex and vesicular compartments
were overrepresented, indicating a specific role for these processes in a-synuclein inclusion formation. Suppressors include
aging-associated genes, such as sir-2.1/SIRT1 and lagr-1/LASS2. Altogether, our data suggest a link between a-synuclein
inclusion formation and cellular aging, likely through an endomembrane-related mechanism. The processes and genes
identified here present a framework for further study of the disease mechanism and provide candidate susceptibility genes
and drug targets for Parkinson’s disease and other a-synuclein related disorders.
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Introduction
Sporadic as well as familial Parkinson’s disease are characterized
by protein inclusions in the brain containing a-synuclein [1]. Similar
inclusions are also present in other neurodegenerative diseases,
including dementia with Lewy bodies [2]. The a-synuclein gene is
causatively related to Parkinson’s disease, since mutations in the
gene, and duplication or triplication of the a-synuclein locus cause
familial forms of Parkinson’s disease in humans [3–5]. Sporadic
Parkinson’s disease, seen in 1–4% of the population over 65 years of
age, appears to be unrelated to mutations or multiplications of the a-
synuclein locus. How a-synuclein inclusions are produced is
unknown, but identifying cellular factors and processes involved
in the formation of these inclusions may provide some understand-
ing of the molecular cause of Parkinson’s disease and of the link
between aging and the sporadic form of the disease. To study
pathological a-synuclein accumulation, we used a genetic model
organism, the nematode Caenorhabditis elegans. We chose C. elegans for
its thoroughly characterized aging properties, its amenability to
genome-wide RNAi screening, and its transparency throughout its
lifetime, which allows visualization of inclusions in living animals
during aging. We expressed human a-synuclein fused to yellow
fluorescent protein in the body wall muscle of C. elegans, where it,
age-dependently, accumulated into inclusions. In old age these
inclusions contained aggregated material, similar to human
pathological inclusions. We used a genome-wide RNAi screen to
identify genes and cellular processes involved in age-related a-
synuclein accumulation in inclusions.
Results/Discussion
To visually trace expression of a-synuclein, we expressed human
a-synuclein fused to yellow fluorescent protein (YFP) in C. elegans
under control of the unc-54 promoter, which drives expression to
the body wall muscle cells. Muscle expression rather than neuronal
expression was chosen for several reasons. The unc-54 promoter is
strong and muscle cells are large, allowing for visual detection of a-
synuclein expression and its subcellular localization. Furthermore,
RNAi by feeding seems to work more efficiently in muscles than in
neurons, which better allows for genome-wide RNAi screening.
Finally, muscle expression has been used successfully to model
protein-misfolding diseases and to identify modifier genes in
previous studies [6–8]. The a-synuclein-YFP chimaeric protein is
recognized by an antibody specific for human a-synuclein and an
antibody for YFP (Figure 1B). YFP fused to human a-synuclein
relocates to inclusions (Figure 1A), which are visible as early as day
2 after hatching and increase in number and size during the
animals’ aging up to late adulthood. As YFP alone remains
diffusely localized throughout aging, this indicates that relocation
of a-synuclein-YFP into foci is caused by intrinsic properties of the
a-synuclein protein.
One of the characteristics of late inclusions in the brains of
Parkinson’s patients is the presence of electron-dense filamentous
and granular protein material, which is typical for aggregated
protein [9]. To address whether a-synuclein was aggregated within
the inclusions in our C. elegans model, we measured the mobility of
the a-synuclein-YFP chimaera by fluorescence recovery after
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photo bleaching (FRAP) [10]. We observed two types of inclusions.
One type contained mostly mobile material (Figure 2P–2T, 2W;
,80% fluorescence recovery), whereas the other type contained
immobilized material (Figure 2K-2O, 2X; ,40% fluorescence
recovery), similar to Q40- YFP aggregates (Figure 2F-2J, V;,30%
fluorescence recovery), indicating aggregated protein, a charac-
teristic of a-synuclein deposits in Parkinson’s disease.
Notably, there was an increase in the number of ‘‘immobile’’
inclusions relative to ‘‘mobile’’ inclusions during aging (Figure 2Y
and 2Z), which appeared unrelated to the expression level of
a- synuclein-YFP (Figure 1C). Interestingly, immobile inclusions
were not observed before late adulthood, which is consistent with
age-related aggregation in Parkinson’s disease patients [11]. We
noted that the motility of the mobile material contained in
inclusions was similar at all ages, suggesting that aggregation was
not a gradual process but caused by a sharp transition from mobile
to immobile material (data not shown). Taken together, the time-
dependent accumulation and immobilization of a-synuclein in
inclusions verify the suitability of our a-synuclein-YFP C. elegans
system as a model for human Parkinson’s disease.
To identify processes involved in inclusion formation we
searched for genes that, when inactivated, increased the amount
of inclusions using a genome-wide RNAi screen. Worms were
screened by visual inspection using fluorescence microscopy at
days 4 and 5 after transfer of synchronized, first stage (L1) larvae to
RNAi clones. Clones were scored positive when at least five out of
the first ten worms screened showed an increase in the amount of
inclusions (Figure 3). Genes for which RNAi results were
confirmed in duplicate, in liquid culture and on agar plates, were
considered suppressors of inclusion formation.
In this screen we found 80 suppressors of inclusion formation
(Table 1). Forty-nine of these genes have an established human
ortholog (Blast E-value #2.5e-5), indicating involvement of these
genes in molecular pathways conserved between humans and
nematodes (Table S1 online). The effect of RNAi was confirmed in
genetic deletion strains for three genes: sir-2.1, an NAD+-
dependent protein deacetylase, lagr-1, a sphingolipid synthase,
and ymel-1, a mitochondrial protease, which is an ortholog of the
human presenilin associated metalloprotease (PAMP) (Figure 4).
The modifier genes function in a variety of biological processes,
some of which have previously been suggested to be involved in
Parkinson’s disease, such as vesicular transport and lipid
Figure 1. A-synuclein-YFP in Transgenic Animals Relocalizes to Discrete Inclusions during Aging. (A) Confocal laser scanning images
showing a-synuclein-YFP expression in the head region of transgenic C. elegans during aging. (B) Immunoblotting analysis of SDS/PAGE separated
protein extracts from a-synuclein-YFP, N2 (wt) and YFP animals using a-synuclein (LB509) and YFP (anti-GFP) antibodies. Loading control is a-actin. (C)
Immunoblotting analysis of protein extracts from 3-, 5-, 11- and 17-day old a-synuclein-YFP synchronized animals using anti-a- synuclein antibody.
doi:10.1371/journal.pgen.1000027.g001
Author Summary
Parkinson’s disease is the second most common brain
disorder of the elderly. It is thought to be caused by
environmental and genetic factors. However, little is
known about the genes and processes involved. Patho-
logically, Parkinson’s disease is recognized by inclusions in
the brain that contain a disease-specific protein: alpha-
synuclein. We created a small animal model (C. elegans) in
which we could follow the formation of alpha-synuclein
inclusions in living and aging animals. With a genome-
wide RNAi screen we identified 80 genes whose expression
influences inclusion formation. These genes include
evolutionarily conserved regulators of longevity, suggest-
ing a link between inclusion formation and the molecular
mechanism of aging. Our results offer a refined under-
standing of how Parkinson’s disease arises during aging
and we identify processes and genes that may underlie an
increased susceptibility for the disease, which is important
for improving diagnostics and developing strategies for
therapeutic intervention.
Modifiers of a-Syn Inclusion Formation
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metabolism. Lipid metabolism, lipid membranes, and vesicle-
mediated transport have previously been linked to a-synuclein
pathology in a yeast model [12,13]. In Parkinson’s patients, lipids
and membrane material have been found to be directly associated
with a-synuclein in lipid droplets and Lewy bodies [11,14–16].
Although we did identify a C. elegans ortholog of the recently
discovered modifier of neuronal alpha-synuclein toxicity SIRT2,
we did not pick up two other modifiers of neuronal alpha-
synuclein pathology: the G-protein coupled receptor kinase 2
and the molecular chaperone Hsp70 [17–19]. In Drosophila,
overexpression of G-protein coupled receptor kinase 2 (Gprk2)
increases neuronal toxicity of a-synuclein [18]. In addition,
expression of an S129A mutant of a-synuclein, which cannot be
phosphorylated by Grpk2, is less toxic, while forming more
aggregates [18]. Based on these observations, one might expect
that knockdown of Gprk2 would result in an increase in the
Figure 2. Fluorescent Recovery after Photo Bleaching Reveals a-Synuclein Inclusions Contain Mobile as well as Immobilized Protein
Material. (A,F,K,P) Images of YFP, Q40-YFP and a-synuclein-YFP transgenic animals. (B-E,G-J, L-O,Q-T) High magnification images of the area
indicated (red box) before photo bleaching and during recovery. (U-X) Graphical representation of fluorescence recovery after photo bleaching in (B-
E, G-J, L-O, Q-T). Relative fluorescence intensity (RFI) value on y-axis represents percentage fluorescence corrected for background bleaching. (Y)
Average number of inclusions larger than ,2 mm2 per animal between tip of the nose and pharyngeal bulb during aging (n = 9 for day 11, n = 10 for
days 9, 13, 15 and 17). (Z) Percentage of foci containing immobile material during aging. Bar in d-g represents 50 mm (overview) and 5 mm in higher
magnification images. Error bars in (Y) indicate standard deviation.
doi:10.1371/journal.pgen.1000027.g002
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amount of inclusions as well. Two orthologs of the Gprk2 gene are
present in C. elegans, grk-1 and grk-2. We tested the effect of
knockdown of these two genes by RNAi on the formation of
inclusions. Unexpectedly, RNAi knockdown of grk-1 or grk-2, and
not RNAi of random tyrosine or serine kinases, resulted in a
decrease in the amount of inclusions (Figure 5A and data not
shown), indicating that we could not have recovered these genes in
our screen for more inclusions. There was no obvious difference in
the level of a-synuclein-YFP expression at day 5 after synchroni-
zation, indicating that formation of the inclusions themselves is
affected (Figure 5D). The effect of knockdown of grk-1 and grk-2 by
RNAi was confirmed by crossing in deletion alleles of both genes,
grk-1(ok1239) and grk-2(gk268), into the a-synuclein-YFP strain
(Figure 5B). Note that an RNAi screen for a reduction in the
amount of inclusions yielded only one other kinase, which supports
the idea that GRKs act specifically (data not shown). In all, C.
elegans orthologs of Gprk2 act as modifiers of a-synuclein inclusion
formation. Knockdown of Gprk2 in Drosophila or overexpression of
grk-1 or grk-2 in C. elegans will be required to establish whether their
specific role in alpha-synuclein pathology is comparable between
the two species.
While Gprk2 overexpression increases toxicity of a-synuclein in
Drosophila, Hsp70 overexpression has been shown to decrease its
toxicity [19]. Because we did not recover Hsp70 as a modifier in
our screen, we tested RNAi for the Hsp70 (C12C8.1) gene
independently. Knockdown by RNAi of Hsp70 did not obviously
increase the amount of inclusions, whereas the same RNAi clone
did increase the amount of inclusions in a polyglutamine worm
(Figure 6). This result is consistent with the findings in Drosophila–
that the decreased toxicity in the presence of Hsp70 is
independent of a change in the amount of alpha-synuclein
inclusions [19]. Apart from a direct role in the detoxification of
misfolded monomers or oligomers of alpha-synuclein, Hsp70 in
Drosophila neurons may also act indirectly, for example as an
inhibitor of apoptosis, which may be independent of aggregation
[20].
To further characterize the inclusion mechanism, we classified
the complete set of identified modifiers according to seven
subcellular locations as annotated by the UniProt entries of the
human orthologs (see Table S1) and compared this classification
with that of sets of random genes (Figure 7A). This analysis
revealed that the number of genes that function in the ER-Golgi
and vacuolar compartment are more than 2-fold higher (p,0.005)
and more than 3-fold higher (p,0.001), respectively, than would
be expected by chance (Figure 7A).
A number of these endomembrane-localized genes are involved
in vesicle-mediated trafficking, protein quality control, and
detoxification of the ER (Table 2). Of particular interest is the
cytochrome P450 gene (cyp-34A7), whose closest human ortholog
inactivates neurotoxic compounds that are known to increase the
risk of developing Parkinson’s disease in humans, such as
organophosphate insecticides and paraquat [16,21–23].
We also identified several molecular regulators of lifespan as
modifiers of inclusion formation, such as lagr-1, a sphingolipid
synthase, and sir-2.1, the C. elegans homolog of Sirtuin1, both of
which we confirmed by crossing the deletion strain for both genes,
lagr-1(gk331) and sir-2.1(ok434), into the a-synuclein strain (Figure 4
A–4D) [24]. Deletion of sir-2.1 or lagr-1 both result in an increase
of approximately 35% in the number of a-synuclein inclusions in
nine-day old adult worms (Figure 4 A-4D). The homolog of lagr-1
in yeast, LAG1, regulates its lifespan and is homologous to LASS2
in humans. Sirtuin-1 is an NAD+-dependent protein deacetylase,
which regulates lifespan in yeast, fruit fly and C. elegans [25–28]. In
C. elegans, overexpression of sir-2.1, the homolog of human sirtuins
1 to 3, extends its lifespan by up to 50%, probably by inhibiting
expression of ER-stress genes [25,26]. These findings suggest a link
between the molecular mechanism of aging and a-synuclein
pathology.
In all, our screen recovered genes and processes that have
previously been identified in other cell or animal models as
modifiers of neuronal a-synuclein toxicity, such as sir-2.1 and
genes involved in vesicle trafficking [12,17,29]. Based on these
findings, we expect other genes from our screen to provide insight
into neuronal a-synuclein pathology as well. Future studies in
neurons will resolve which of these gene processes are implicated
in neuronal a-synuclein pathology.
In a screen performed previously for modifiers of polyglutamine
aggregation in C. elegans, we found a large variety of proteasomal
genes and chaperones [6]. These genes are typically found to be
involved in protein misfolding and aggregation and are suggested
to be generally involved in protein-misfolding diseases. Surpris-
ingly, very few of such genes were found in the a- synuclein screen.
Figure 3. Suppressors of Inclusion Formation Identified by RNAi. (A) Confocal images showing head region of a-synuclein-YFP transgenic
animals fed on OP50 bacteria, bacteria containing L4440 (empty vector) and expressing double stranded RNA targeting two representative genes
(F26H11.4 and Y48G1A.6) found to increase inclusion formation. Phenotypes of increased inclusion formation were analyzed in liquid culture by
observing at least five out of the first ten animals screened to show an increased presence of inclusions compared to wild type. Scale bar represents
50 mm. (B) Quantification of the number of inclusions present in worms as shown in (A) (n = 2).
doi:10.1371/journal.pgen.1000027.g003
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Only a single gene found to increase a-synuclein inclusion
overlapped with the screen for polyglutamine aggregation we
performed in C. elegans. Perhaps even more strikingly, the modifiers
of polyglutamine aggregation that we had identified previously
located primarily to cytosol and nucleus (Figure 7B) [6]. This
suggests that different cellular processes are involved in preventing
the development of inclusions in these protein-misfolding disor-
ders. In conclusion, we have developed a transgenic C. elegans
model showing a-synuclein inclusions that share important
characteristics of inclusions in Parkinson’s disease. The formation
of inclusions shows a strong age-dependency and clearly distinct,
consecutive phases of progressive aggregation. Our transgenic
worms therefore provide a versatile model for the characterization
of the molecular steps preceding pathologic inclusion formation. In
a global RNAi screen we identified modulators of a-synuclein
aggregation that are distinct from those in other protein-
aggregation disorders. Most importantly, our list of suppressors
of age-dependent inclusion formation reveals a clear link between
a-synuclein inclusion formation and cellular aging, most probably
via an endomembrane-related mechanism. Our results provide an
important guide for further elucidation of the pathogenic
mechanisms and genetic susceptibility factors in human Parkin-
son’s disease and other a-synuclein related disorders.
Materials and Methods
Constructs
To create P(unc-54)a-synuclein: YFP (pRP2386) a-synuclein
was amplified from cDNA (provided by S. Lindquist, MIT, MA)
by PCR using primers adding a KpnI and a AgeI site, respectively
(39-agcgtcgacggtaccgcgatggatgtattcatgaaagg-59, 39- gactacgaacct-
gaagcctccaccggt cgccacctc-59), to the a-synuclein gene, which was
then cloned into the pPD30.38-YFP expression vector.
Media and Strains
Standard conditions were used for C. elegans propagation at
20uC. Worms were synchronized by hypochlorite bleaching,
hatched overnight and were subsequently cultured on NGM
plates with OP50. On day 3 after synchronization, worms were
placed on NGM plates containing 5- Fluoro-29deoxy-uridine
(FUDR) to prevent eggs from hatching. The following strains
were used: NL5901 (pkIs2386 [a-synuclein::YFP unc-
119(+)]),VC199(ok434), OW8 (sir- 2.1(ok434)IV; pkIs2386[a-
synuclein::YFP unc-119(+)]), VC765(gk331), OW13 (grk-
1(ok1239)X; pkIs2386[a-synuclein::YFP unc-119(+)]),OW15
(grk-2(gk268)III; pkIs2386[a-synuclein::YFP unc-119(+)]),OW6
(ymel-1(tm1920)III; pkIs2386[a-synuclein::YFP unc-119(+)]),
OW101 (lagr-1(gk331)I; pkIs2386[a-synuclein::YFP unc-119(+)]),
AM134 (rmIs126[P(unc-54)Q0::YFP]), and AM141 (rmIs133[-
P(unc-54) Q40::YFP]) [7]. The a-synuclein YFP fusion is driven by
an unc-54, muscle specific, promoter to obtain expression in the
body-wall muscle cells. Muscle expression was chosen to allow for
efficient RNAi and for visual detection of inclusions [6–8].
Creation of Transgenic Strains
Transgenic C. elegans were generated using standard ballistic
transformation by co-bombarding unc-119 rescue vector
(pRP2512) and the a-synuclein-YFP expression construct into
unc- 119(ed3) nematodes [30].
Immunoblotting Analysis
Nematode protein extracts were prepared from whole animal
frozen pellets in PBS containing proteinase inhibitors (Roche,
Indianapolis, USA) by using Fastprep24 (MP, Solon, USA).
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Figure 4. Sir-2.1, ymel-1 and lagr-1 Are Suppressors of a-Synuclein Inclusion Formation. (A,B) Confocal images showing a-synuclein-YFP
transgenic animals and the transgenic strains containing a deletion in the sir-2.1gene (sir-2.1(ok434)) on day 9. (C) Average number of inclusions between
tip of the head and pharyngeal bulb of the worm (n=8). *P#0.025 (Student’s t test). (D, E, F) Confocal images showing a-synuclein-YFP transgenic worms
and the transgenic strains containing a deletion in the ymel-1and lagr-1 gene (ymel-1(tm1920) and lagr-1(gk331)), on day 9. (G) Average number of
inclusions between tip and pharyngeal bulb of the worm (n=8 (wt and ymel-1), n = 7 (lagr-1)). *P#0.05, **P#0.05 (Student’s t test).
doi:10.1371/journal.pgen.1000027.g004
Figure 5. RNAi and Deletion of grk-1 and grk-2 Decreases Inclusion Formation. (A) Confocal images showing head region of a-synuclein-YFP
transgenic animals fed on OP50 bacteria, bacteria containing empty RNAi vector (L4440), and expressing double stranded RNA targeting grk-1 and
grk-2. (B) Confocal images of a-synuclein-YFP C. elegans, in wild type background, grk-1(ok1239) and grk-2(gk268) background. Scale bar represents
25 mm. (C) Quantification of the number of worms within the population (n = 20) with the same amount (wt), fewer (,wt) or no inclusion (none). (D)
Western blot analysis of protein extracts from 20 staged transgenic C. elegans with a grk-1 or grk-2 genetic deletion showing similar levels of fusion
protein expressed and actin (loading control).
doi:10.1371/journal.pgen.1000027.g005
Modifiers of a-Syn Inclusion Formation
PLoS Genetics | www.plosgenetics.org 8 2008 | Volume 4 | Issue 3 | e1000027
Samples were boiled 5 min with sample buffer containing SDS
and DTT, and separated on 10% SDS/PAGE. Proteins were
transferred to PVDF membranes. Antibody binding was visualized
by binding of horse-radish peroxidase-coupled secondary antibody
and chemiluminescence (ECL Lumi-Light, Roche, Germany).
Antibodies used were a-synuclein (1:3,000; LB509, Zymed, San
Francisco, USA), anti-actin (1:8,000; Clone C4, ICN, Aurora,
OH, USA) and anti-GFP polyclonal serum [31]. Goat-anti-mouse
and goat-anti-rabbit IgG-HRP (1:5,000; BioRad, Hercules, CA,
USA) were used as secondary antibodies.
CLSM and Fluorescence Recovery after Photo Bleaching
(FRAP)
Transgenic worms were mounted on 2% agarose pads
containing 40 mM NaN3 as anaesthetic on glass microscope
slides. Images were captured using a Leica DMIRE2 confocal
microscope with an x40 oil immersion lens (HCX PL APO CS).
Images shown are 2D maximal projections of zseries. Immobi-
lized animals were subjected to FRAP analysis with minor
modifications as described [20]. An area of ,4 mm2 was
bleached for 5 s (five iterations at 100% intensity), after which
images were collected (at low intensity). Relative fluorescence
intensities (RFI) were calculated as described by using the
RFI = (Net/N1t)/(Ne0/N10) equation [10]. For quantification of
the number and motility of inclusions (Figure 1 y and z) all foci
larger than 2 mm2 between the nose and pharyngeal bulb were
analyzed by FRAP. Measurements on inclusions were performed
using ImageJ software [26]. Statistical significance was deter-
mined using t tests.
RNAi Screen
Synchronized larvae were grown in liquid culture in 96-well
plates, on bacterial strains from the Ahringer bacterial RNAi
library as described [6,32]. Worms grown on the different RNAi
clones were visually selected for increased inclusion formation four
and five days after bleaching. Bacterial clones, that exhibited
increased inclusion formation, were confirmed in an independent
experiment in duplicate in liquid culture. RNAi clones confirmed
to increase inclusion formation were then fed to a-synuclein-YFP
transgenic C. elegans on NGM plates for reconfirmation. All gene
targets of the positive-RNAi foods were verified by sequencing of
the insert of the RNAi plasmids.
Bioinformatics and Statistical Analysis
Subcellular location data were tested for overrepresentation
using expected relative frequencies based on a Poisson distribution
(e-mmY/Y!), where Y is the observed percentage of genes observed
for a given class (Y) and m is the expected (mean) percentage of this
class among all annotated genes. The observed results were
compared to a random list of 55 genes (n = 20) created from
Figure 7. Subcellular Distribution a-Synuclein Modifiers. (A) and
(B) bar graphs showing the percentage of genes within each subcellular
location class for the genes identified in the a-synuclein modifier screen
(A), the polyglutamine modifier screen (B) versus random lists of genes.
Random genes were obtained from UniProt (Universal Protein
Resource). The subcellular quantities were calculated by adding up
the subcellular annotation for 20 sets of 55 randomly chosen proteins
(black bars). Values shown are average (n = 20, error bars indicate
standard deviation). (A) Overrepresentation of genes in ER/Golgi class
and vesicular class in the a-synuclein screen (P-values for the differences
between the number of observed genes in ER/Golgi and vesicular class
and the number expected: P,0.005 and P,0.001). (B) Overrepresen-
tation of genes in cytoplasm and nucleus in the polyglutamine screen
(P-values for the differences between the percentage of observed
genes in cytoplasm and nucleus and the number expected: P,0.001
and P,0.02).
doi:10.1371/journal.pgen.1000027.g007
Figure 6. RNAi of hsp-70 Does Not Affect Inclusion Formation.
(A) Confocal images showing Q24-YFP, Q35-YFP and a-synuclein-YFP
transgenic animals fed on bacteria containing empty RNAi vector
(L4440), and expressing double stranded RNA targeting hsp-70.
doi:10.1371/journal.pgen.1000027.g006
Modifiers of a-Syn Inclusion Formation
PLoS Genetics | www.plosgenetics.org 9 2008 | Volume 4 | Issue 3 | e1000027
random UniProt entries with annotated subcellular locations.
Genes functioning in more than one location were assigned to
both locations.
Supporting Information
Table S1 Human orthologs.
Found at: doi:10.1371/journal.pgen.1000027.s001 (0.08 MB
XLS)
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